About Us
DELFI Diagnostics Inc. (DELFI Diagnostics) is developing next-generation blood-based tests that are reliable accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data the DELFI (DNA EvaLuation of Fragments for early Interception) platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale including for historically underserved populations. DELFI Diagnostics platform relies on fragmentomics the discovery that cancer cells are more chaotic than normal cells and when they die leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung for individuals eligible for lung cancer screening is DELFI Diagnostics first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT including early-stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In our passionate pursuit to radically improve health outcomes we serve humanity when we :
Lead with Science Anchor in Pragmatism : We pioneer life-changing science by ensuring quality transparency and rigor at all times. We explore thoughtfully experiment smartly and deliver impact with conviction.
Build With & For All : We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
Put We over I : We are a home for high-performing people. Through teamwork we build collective intelligence. Each of us wins when those we serve and those who serve with us win. We show up with empathy humility and integrity at every step of the journey.
About the Role
Join our innovative team dedicated to reducing cancer deaths through cutting-edge liquid biopsy diagnostics. As Sr. Research Associate you will play a critical role in developing and validating next-generation sequencing assays from concept through commercial launch working within a collaborative environment of scientists engineers and bioinformaticians. You will contribute to product development verification and validation activities for NGS-based laboratory tests for early cancer detection. The ideal candidates would have experience working under Good Laboratory Practice (GLP) in a CAP / CLIA / FDA-regulated environment.
What youll do
What youll have accomplished 6 months from now
What youll bring to DELFI
Preferred qualifications :
$110000 - $135000 a year
An equal opportunity employerWe are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race religion color national origin gender sexual orientation age marital status veteran status or disability status.
We may use artificial intelligence (AI) tools to support parts of the hiring process such as reviewing applications analyzing resumes or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed please contact us.
Required Experience :
Senior IC
Key Skills
Laboratory Experience,Immunoassays,Mammalian Cell Culture,PCR,Biochemistry,Assays,Cell Biology,Research Experience,Cell Culture,Molecular Biology,Flow Cytometry,Western Blot
Employment Type : Contract
Experience : years
Vacancy : 1
Senior Research Associate • Palo Alto, California, USA